CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population

Pharmacogenetics

Volumn 6, Issue 4, 1996, Pages 329-339

  Jurima Romet, Malle ^a   Goldstein, Joyce A ^b   LeBelle, Michael ^a   Aubin, Rémy A ^a   Foster, Brian C ^a   Walop, Wikke ^c   Rode, Andris ^d  

^a Bureau of Drug Research   (Canada)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c HEALTH CANADA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

CYP2C19; Genotype; Inuit; Phenotype

Indexed keywords

4' HYDROXYMEPHENYTOIN; CAFFEINE; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; DNA; DRUG METABOLITE; MEPHENYTOIN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CANADA; CAPILLARY GAS CHROMATOGRAPHY; CAUCASIAN; CLINICAL TRIAL; DROWSINESS; DRUG URINE LEVEL; ENANTIOMER; ESKIMO; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; VERTIGO;

EID: 0029760287     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199608000-00006     Document Type: Article

References (47)

1. Andersson T, Regärdh C-G. Dahl-Puustinen M-L. Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990: 12, 415-416.
2. Armour JAL, Povey S, Jeremiah S, Jeffreys AJ. Systematic cloning of human minisatellites from ordered array charomid libraries. Genomics 1990: 8, 501-512.
3. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989: 45, 348-355.
4. Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, Wang, K-Y, Reviriego J, Iselius L. Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992: 51, 388-397.
5. Bragg T, Nakamura Y, Jones C, White R. Isolation and mapping of a polymorphic DNA sequence (cTBQ7) on chromosome 10 [D10S28]. Nucleic Acids Res 1988: 16, 11 395.
6. Breimer DD, Schellens JHM, Soons PA. Assessment of in vivo oxidative drug metabolizing enzyme activity in man by applying a cocktail approach, in: Miners J, Birkett DJ, Drew R, McManus M, editors. Proceedings of the VIIth International Symposium on microsomes and drug oxidations. (Adelaide 17 to 21 August 1987). London: Taylor and Francis, 1988: pp. 232-240. Cited by Alvan G. Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations, Eur J Clin Pharmacol 1990: 38, 533-537.
7. Breimer DD, Schellens JHM, Soons PA. Assessment of in vivo oxidative drug metabolizing enzyme activity in man by applying a cocktail approach, in: Miners J, Birkett DJ, Drew R, McManus M, editors. Proceedings of the VIIth International Symposium on microsomes and drug oxidations. (Adelaide 17 to 21 August 1987). London: Taylor and Francis, 1988: pp. 232-240. Cited by Alvan G. Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations, Eur J Clin Pharmacol 1990: 38, 533-537.
8. Brockmöller J. Rost KL, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantificalion of R-and S-mephenytoin and comparison with the intron4/exon5 G → A-splice site mutation. Pharmacogenetics 1995: 5, 80-88.
9. Brosen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995: 5, 312-317.
10. Cavalli-Sforza LL, Piazza A, Menozzi P, Mountain J. Reconstruction of human evolution: bringing together genetic, archeological, and linguistic data. Proc Natl Acad Sci USA 1988: 85, 6002-6006.
11. Chang M, Dahl M-L, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995: 5, 358-363.
12. Clasen K, Madsen L, Brosen K, Alboge K, Misfeldt S, Gram LF. Sparteine and mephenytoin oxidation: genetic polymorphisms in East and West Greenland. Clin Pharmacol Ther 1991: 49, 624-631.
13. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994a: 269, 15419-15422.
14. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994b: 46, 594-598.
15. de Morais SMF, Bell DA, Goldstein JA. Incidence of CYP2C19 mutants in American-European, African-American and Chinese-Taiwanese individuals. ISSX Proceedings of the Sixth North American ISSX Meeting 1994c: 6, 238.
16. de Morais SMF, Goldstein JA, Xie H-G, Huang S-L, Lu Y-Q, Xia H, Xiao Z-S, Ile N, Zhou H-H. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995: 58, 401-411.
17. Desiderio C, Fanali S, Küpfer A, Thormann W. Analysis of mephenytoin, 4-hydroxymephenytoin and 4-hydroxyphenytoin enantiomers in human urine by cyclodextrin micellar electrokinetic capillary chromatography: simple determination of a hydroxylation polymorphism in man. Electrophoresis 1994: 15, 87-93.
18. Droøhse A, Bathum L, Brosen K, Gram LF. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol 1989: 27, 620-625.
19. Fourney RM, Gaudette BD. A protocol for DNA typing by restriction length polymorphism (RFLP) analysis using single locus probes. In: Proceedings of the American Chemical Society on DNA Technologies. 1995, in press.
20. Frégeau CJ, Aubin RA, Elliott JC, Gill, Fourney RM. Characterization of human lymphoid cell lines GM9947 and GM9948 as intra- and interlaboratory reference standards for DNA typing. Genomics 1995: 28, 184-197.
21. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Rauch JL, et al. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 1994: 33, 1743-1752.
22. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou H-H Zhou B-J. Liao C-L, Zhang L-M. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989: 46, 198-207.
23. Inaba T, Jurima M, Kalow W. Family studies of mephenytoin hydroxylation deficiency. Am J Hum Genet 1986: 38, 768-772.
24. Jacqz E, Dulac H, Mathieu H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 1989: 35, 167-171.
25. Jones, DA. Blood samples: Probability of discrimination. J Forens Sci Soc 1972: 12, 355-359.
26. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Oriental and Caucasians. Br J Clin Pharmacol 1985: 19, 483-487.
27. Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984: 26, 755-759.
28. McAlpine PJ, Chen S-H, Cox DW, Dossetor JB, Giblett E, Steinberg AG, Simpson NE. Genetic markers in blood in a Canadian Eskimo population with a comparison of allele frequencies in circumpolar populations. Human Heredity 1974: 24, 114-142.
29. Meltzer DJ. Pleistocene peopling of the Americas. Evolutionary Anthropol 1993: 1, 157-169.
30. Monson KL, Budowle B. A system for semiautomated analysis of DNA autoradiograms. In: Proceedings of an International Symposium on the Forensic Aspects of DNA Analysis, U.S. Government Printing Office, Washington, DC. 1990: 127-132.
31. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985: 38, 402-408.
32. Nakamura Y, Gilillian S, O'Connell P, Leppert M, Lathrop GM, Lalouel J-M, White R. Isolation and mapping of a polymorphic UNA sequence pYNH24 on chromosome 2 [D2S44]. Nucleic Acids Res 1987a: 15, 10073.
33. Nakamura Y, Leppert M, O'Connell P, Wolff R, Holm T, Culver M, Martin C, Fujimoto E, Hoff M, Kumlin E and White R. Variable number of tandem repeat (VNTR) markers for human gene mapping. Science 1987b: 235, 1616-1622.
34. Reviriego J, Bertilsson L, Carrillo JA, Llerena A, Valdivielso MJ, Benítez J. Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations. Eur J Clin Pharmacol 1993: 44, 593-595.
35. Sanz EJ. Villén T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989: 45, 495-499.
36. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jorgensen T, Overo KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993: 13, 11-17.
37. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991: 49, 18-25.
38. Sohn D-R, Kusaka M, Ishizaki T, Shin S-G, Jang I-J, Shin J-G, Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992: 52, 160-169.
39. Szathmary EJE. Genetics of Aboriginal North Americans. Evolutionary Anthropol 1993: 1, 202-220.
40. Tybring G, Bertilsson L. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992: 2, 241-243.
41. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989: 45, 72-79.
42. Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF. Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991: 31, 689-692.
43. Waye JS, Fourney RM, Bowen JH. Forensic analysis of restriction fragment length polymorphism: Theoretical and practical considerations for design and implementation. In: Proceedings from the International Symposium on Human Identification. Promega Corporation 1990: 117-152.
44. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984: 26, 773-780.
45. Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos 1987: 15, 277-279.
46. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993: 306, 240-245.
47. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ. Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991: 31, 350-352.